Oncozenge AB (ONCOZ) - Net Assets
Based on the latest financial reports, Oncozenge AB (ONCOZ) has net assets worth Skr-587.00K SEK (≈ $-63.17K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr15.34 Million ≈ $1.65 Million USD) and total liabilities (Skr15.92 Million ≈ $1.71 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See net asset quality index of Oncozenge AB to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-587.00K |
| % of Total Assets | -3.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | -100.73% |
| 10-Year Change | N/A |
| Growth Volatility | 97.8 |
Oncozenge AB - Net Assets Trend (2020–2025)
This chart illustrates how Oncozenge AB's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Oncozenge AB market capitalisation.
Annual Net Assets for Oncozenge AB (2020–2025)
The table below shows the annual net assets of Oncozenge AB from 2020 to 2025. Also explore ONCOZ net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr-587.00K ≈ $-63.17K |
-105.90% |
| 2024-12-31 | Skr9.95 Million ≈ $1.07 Million |
-46.62% |
| 2023-12-31 | Skr18.64 Million ≈ $2.01 Million |
-45.13% |
| 2022-12-31 | Skr33.97 Million ≈ $3.66 Million |
-57.70% |
| 2021-12-31 | Skr80.32 Million ≈ $8.64 Million |
+174.32% |
| 2020-12-31 | Skr29.28 Million ≈ $3.15 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Oncozenge AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7586400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | Skr98.77 Million | % |
| Total Equity | Skr-587.00K | 100.00% |
Oncozenge AB Competitors by Market Cap
The table below lists competitors of Oncozenge AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FRESH FACTORY B.C.
F:Q4Z
|
$5.29 Million |
|
SATO Technologies Corp
V:SATO
|
$5.30 Million |
|
Green Ocean Corporation Bhd
KLSE:0074
|
$5.30 Million |
|
Llama Group S.A.
PA:ALLAM
|
$5.30 Million |
|
North Stawell Minerals Ltd
AU:NSM
|
$5.29 Million |
|
Technoplus Ventures Ltd
TA:TNPV
|
$5.29 Million |
|
Bullfrog AI Holdings, Inc. Common Stock
NASDAQ:BFRG
|
$5.29 Million |
|
UNIDOC HEALTH CORP.
F:L7T
|
$5.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Oncozenge AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,950,000 to -587,000, a change of -10,537,000 (-105.9%).
- Net loss of 15,940,000 reduced equity.
- New share issuances of 6,043,000 increased equity.
- Other factors decreased equity by 640,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-15.94 Million | -2715.5% |
| Share Issuances | Skr6.04 Million | +1029.47% |
| Other Changes | Skr-640.00K | -109.03% |
| Total Change | Skr- | -105.90% |
Book Value vs Market Value Analysis
This analysis compares Oncozenge AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Skr2.01 | Skr3.50 | x |
| 2021-12-31 | Skr6.86 | Skr3.50 | x |
| 2022-12-31 | Skr2.90 | Skr3.50 | x |
| 2023-12-31 | Skr1.59 | Skr3.50 | x |
| 2024-12-31 | Skr0.85 | Skr3.50 | x |
| 2025-12-31 | Skr-0.05 | Skr3.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Oncozenge AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -598.35%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-52.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -2.17% | 0.00% | 0.00x | 1.31x | Skr-3.56 Million |
| 2021 | -4.84% | 0.00% | 0.00x | 1.06x | Skr-11.92 Million |
| 2022 | -137.30% | 0.00% | 0.00x | 1.09x | Skr-50.04 Million |
| 2023 | -85.31% | -530066.67% | 0.00x | 1.09x | Skr-17.77 Million |
| 2024 | -87.32% | -868800.00% | 0.00x | 1.15x | Skr-9.68 Million |
| 2025 | 0.00% | -598.35% | 0.17x | 0.00x | Skr-15.88 Million |
Industry Comparison
This section compares Oncozenge AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,474,578
- Average return on equity (ROE) among peers: -114.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Oncozenge AB (ONCOZ) | Skr-587.00K | -2.17% | N/A | $5.29 Million |
| 2cureX AB (2CUREX) | $43.03 Million | -69.18% | 0.11x | $1.13 Million |
| Ascelia Pharma AB (publ) (ACE) | $237.06 Million | -16.83% | 0.06x | $8.55 Million |
| AcouSort AB (ACOU) | $8.46 Million | -178.16% | 0.46x | $6.79 Million |
| Active Biotech AB (ACTI) | $46.67 Million | -106.88% | 0.22x | $12.40 Million |
| Alzinova AB (ALZ) | $947.42K | -195.83% | 0.18x | $9.77 Million |
| AlzeCure Pharma (ALZCUR) | $60.48 Million | -92.65% | 0.17x | $95.72 Million |
| Annexin Pharmaceuticals AB (ANNX) | $2.71 Million | -51.19% | 0.36x | $9.14 Million |
| Alligator Bioscience AB (ATORX) | $115.24 Million | -124.61% | 0.32x | $2.29 Million |
| BioInvent International AB (BINV) | $55.63 Million | -317.55% | 1.27x | $158.27 Million |
| BioArctic AB (publ) (BIOA-B) | $974.50 Million | 9.08% | 0.21x | $2.57 Billion |
About Oncozenge AB
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.